



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	20248	BLACKMORES DUO CELLOIDS S.C.F. tablet
ARTG entry for	Medicine Registered	
Sponsor	FIT-BioCeuticals Limited	
Postal Address	PO Box 6454, ALEXANDRIA, NSW, 2015 Australia	
ARTG Start Date	14/10/1991	
Product Category	Medicine	
Status	Active	
Approval Area	Registered Complementary Medicines	

Conditions

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Conditions Applying to Therapeutic Goods Accepted for Registration or Listing as Goods Currently Supplied at the Commencement of the Therapeutic Goods Act 1989"

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Products

1 . BLACKMORES DUO CELLOIDS S.C.F. tablet

Product Type	Single Medicine Product	Effective Date	19/06/2018
---------------------	-------------------------	-----------------------	------------

Permitted Indications

No Permitted Indications included on Record

Indication Requirements

No Indication Requirements included on Record

Standard Indications

No Standard Indications included on Record

Specific Indications

Mineral supplement.

Warnings

No Warnings included on Record

Additional Product information

Container information

Type	Material	Life Time	Temperature	Closure	Conditions
Bottle	Not recorded	4 Years	Store below 30 degrees Celsius	Not recorded	Store in a Dry Place Protect from Light

Pack Size/Poison information

Pack Size	Poison Schedule
170 tablets	Not Scheduled after consideration by Committee
84 tablets	Not Scheduled after consideration by Committee

Components

1 .

Dosage Form	Tablet, uncoated
Route of Administration	Oral
Visual Identification	Round white biconvex tablet with embossed 'b' & breakbar

Active Ingredients

Public Summary



Australian Government
Department of Health
Therapeutic Goods Administration

calcium fluoride	500 ng
silicon dioxide	33 mg

Other Ingredients (Excipients)

Acacia
lactose monohydrate
magnesium stearate
maize starch
microcrystalline cellulose
soy polysaccharide

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary